Neoplasms

Digestive System Diseases

All Conditions

Gland and Hormone Related Diseases

Symptoms and General Pathology

Rare Diseases

Stomach Neoplasms

Pancreatic Neoplasms

Polyps

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Endocrine Gland Neoplasms

Pancreatic Diseases

Endocrine System Diseases

Pathological Conditions, Anatomical

Stomach Cancer

Pancreatic Cancer

Adult patients above the age of 18 years with gastric, colorectal (including pre-cancer polyps) or pancreatic cancer

Each participant will give a sample of saliva through spitting for 10 minutes in a sterile tube.

Salivary samples

Hadas Lemberg, PhD

Moti Moskovitz, DMD, PhD

Eyal Shtayer, MD

Avi Levin, MD

Colorectal cancers account for 783,000 new cases and cause 437,000 deaths per year across the world. Diagnosis in the early stages improves survival rates. Up to now, these cancers are mostly diagnosed only at later stages of the disease's course through histoimmune staining and molecular biology processes on the tissues biopsied from the gastrointestinal system under invasive diagnostic procedures of colonoscopy.

Oral fluid presents a large protein complexity and has been recently used as a diagnostic biofluid for oral, as well as systematic diseases. Using oral fluid as a bio-marker for the colorectal cancer can be advantageous as it contains gastrointestinal fluids, in addition to bacteria and bacteria lysate, which can also serve as a bio-markers' source for colorectal cancers. Proteomic technologies provide the tools needed to discover and identify disease-associated biomarkers.

The aim of the present study is to identify salivary bio-markers in patients suffering from colorectal cancers.

Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers

Hadassah Medical Organization

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Ovarian Neoplasms

Carcinoma, Ovarian Epithelial

Cysts

Ovarian Cysts

Carcinoma

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Genital Neoplasms, Female

Urogenital Neoplasms

Gonadal Disorders

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

Ovarian Cancer

Ovarian Epithelial Cancer

For patients with a benign ovarian cyst, 1 saliva sample taken at 3 times (concomitant with a visit performed in routine care):

* During the inclusion visit,
* At the postoperative visit,
* At the 6-month follow-up visit

For patients with ovarian cancer, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):

* At the inclusion visit,
* During the postoperative visit,
* At the follow-up visits (6 months post-surgery and then every 6 months until 24 months)

For patients with a borderline ovarian tumor, 1 saliva sample taken at different times (concomitant with a visit performed in routine care):

* At the inclusion visit,
* During the postoperative visit,
* During pre- and post-chemotherapy visits (before and after each cycle)
* During follow-up visits (every 4 months until 24 months)

Raffaèle Fauvet, Pr

Philippe Descamps, Pr

Laetitia Elisabeth Rocca, Dr

François Golfier, Pr

Mathieu Poilblanc, Dr

Marie Gosset, MD

Sandrine Richard, Dr

Sofiane Bendifallah, Dr

Cyril Touboul, Pr

Emile Darai, Pr

Vincent Lavoué, Pr

Vinvent Lavoué, Pr

Claire Marie Roger, MD

Clotilde Hennetier, MD

Ludivine Genre, MD

Lobna Ouldamer, Pr

Lobna Ouldamer

OVAmiARN is a multicentre, prospective, longitudinal, non-interventional, observational study carried out in 8 obstetrics and gynecology departments in France; in order to describe the evolution of salivary miRNA expression between the pre-operative and post-therapy visits according to the type of mass. In time, the clinical application will be to significantly reduce the time to diagnosis and improve the care pathway for ovarian adnexal mass.

The study population consists of patients with an ovarian adnexal mass diagnosed by clinical examination and imaging (pelvic ultrasound and/or MRI) and requiring surgical management in routine care.

The patients concerned by the study will be managed without modification of the care pathway, nor modification of the therapeutic indications, nor modification of the diagnostic or follow-up examinations (imaging or biology) necessary according to the context, which are carried out according to the recommendations of the HAS, CNGOF.

In this study, the management and follow-up of patients :

* Are not imposed by the study: the doctor remains free to make medical prescriptions (treatments and examinations) and to determine the interval between consultation visits,
* Are not modified in comparison with the usual follow-up, except for the performance of the Collection of saliva

Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin

Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin - OVAmiARN Study

Identifying a signature of ovarian cancer diagnosis by analysis of coding and non-coding RNAs in the saliva of subjects

Monitoring Force Group

iGenSeq

ZIWIG

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
Identifying Saliva Markers of Patients With Stomach, Colorectal (Including Pre-cancer Polyp) and Pancreatic Cancers	NCT01675258	Gastric Cancer Colorectal Canc... Pancreatic Canc...	Salivary sample...	18 Years -	Hadassah Medical Organization
Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin	NCT05514028	Ovarian Cancer Ovarian Cyst Be... Borderline Ovar...	Salivary sample...	18 Years -	ZIWIG
Evaluation of Salivary RNAs in the Presence of an Adnexal Mass of Ovarian Origin	NCT05514028	Ovarian Cancer Ovarian Cyst Be... Borderline Ovar...	Salivary sample...	18 Years -	ZIWIG

Spots Global Cancer Trial Database for salivary samples